Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

677.28
-10.3303-1.50%
Number of Gainers:70
Number of Losers:73
Number of Flat:10
PE:- -
High:699.38
Open:689.92
Low:677.23
Close:687.61
Volume:352.76M
Turnover:11.79B
Market Cap:466.91B
Float Cap:356.34B

Loading ...

UiPath and BDO Expand Partnership to Build Agentic Solution Accelerators for Continuous Monitoring and Testing

THOMSON REUTERS
·
Sep 29

Silexion Therapeutics Announces Exercise of Warrants

GlobeNewswire
·
Sep 29

Acurx Pharmaceuticals Announces First Patient Enrolled in Pathfinder Clinical Trial of Ibezapolstat in Multiply-Recurrent C. Difficile Infection

THOMSON REUTERS
·
Sep 29

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

GlobeNewswire
·
Sep 29

European Wax Center Announces Renowned Esthetician Joanna Czech as First-Ever Brand Ambassador

GlobeNewswire
·
Sep 29

US Stocks on the MOVE-PepsiCo, Coinbase Global, CarMax

Reuters
·
Sep 29

Aquestive Therapeutics Adds Veteran Executive to Board

TIPRANKS
·
Sep 29

Zhihu-W (02390) Spends US$265,100 to Buy Back 207,900 Shares on September 28

Stock News
·
Sep 29

Invivyd Plans FDA Accelerated-Approval BLA Filing for Vyd2311 COVID Antibody

Reuters
·
Sep 29

Deutsche Bank Trims Price Target on Robinhood Markets to $134 From $138, Keeps Buy Rating

MT Newswires Live
·
Sep 29

Unicycive Therapeutics announces resubmission of NDA for OLC

TIPRANKS
·
Sep 29

Aquestive Therapeutics appoints Daly to board of directors

TIPRANKS
·
Sep 29

Unicycive Resubmits FDA NDA for Oxylanthanum Carbonate Phosphate Binder

Reuters
·
Sep 29

Unicycive Therapeutics - FDA Acceptance of Nda Expected Within 30 Days; New Pdufa Date in 6 Months

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics - Nda Resubmission Includes Cmc Data from New Manufacturing Vendor

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

THOMSON REUTERS
·
Sep 29

Unicycive Therapeutics - FDA Inspection of Original Manufacturing Vendor Assigned but not Completed as of Sept 29, 2026

THOMSON REUTERS
·
Sep 29

Invivyd Says Liberty Phase 3 Trial Shows Vyd2311 Safety, Tolerability Top mRNA COVID-19 Vaccine

Reuters
·
Sep 29

Invivyd, - Vyd2311 Combined with Mrna Covid-19 Vaccine Adds to Neutralizing Titers Without Interference

THOMSON REUTERS
·
Sep 29

Invivyd, - Plans Bla Submission for Vyd2311 to FDA Via Accelerated Approval Program

THOMSON REUTERS
·
Sep 29